KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Long-Term Debt Issuances (2016 - 2022)

Historic Long-Term Debt Issuances for Halozyme Therapeutics (HALO) over the last 3 years, with Q3 2022 value amounting to $452.0 million.

  • Halozyme Therapeutics' Long-Term Debt Issuances changed N/A to $452.0 million in Q3 2022 from the same period last year, while for Dec 2023 it was $452.0 million, marking a year-over-year decrease of 3561.25%. This contributed to the annual value of $735.0 million for FY2025, which is N/A changed from last year.
  • Per Halozyme Therapeutics' latest filing, its Long-Term Debt Issuances stood at $452.0 million for Q3 2022.
  • Halozyme Therapeutics' 5-year Long-Term Debt Issuances high stood at $784.9 million for Q1 2021, and its period low was $250.0 million during Q2 2022.